Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.47 |
| ▸ | GRM5 | P41594 | 13/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523752 | 0.92 | HDAC4 (0.53) | HDAC4HDAC6GRM5 | |
| SCHEMBL22265590 | 0.90 | FAAH (0.51) | FAAHMGLLHDAC4HDAC6GRM5 | |
| SCHEMBL22280317 | 0.90 | FAAH (0.51) | FAAHMGLLHDAC4HDAC6GRM5 | |
| SCHEMBL22265697 | 0.84 | FAAH (0.54) | FAAHMGLLHDAC4HDAC6GRM5 | |
| SCHEMBL22265698 | 0.83 | SPHK2 (0.49) | FAAHMGLLHDAC4HDAC6GRM5 | |
| SCHEMBL22266076 | 0.83 | SPHK2 (0.49) | FAAHMGLLHDAC4HDAC6GRM5 | |
| SCHEMBL22265606 | 0.83 | SPHK2 (0.49) | FAAHMGLLHDAC4HDAC6GRM5 | |
| SCHEMBL22265338 | 0.82 | SPHK2 (0.62) | FAAHMGLLHDAC4HDAC6 | |
| SCHEMBL22280474 | 0.82 | HDAC4 (0.54) | HDAC4HDAC6GRM5 | |
| SCHEMBL29523313 | 0.82 | HDAC4 (0.54) | HDAC4HDAC6GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
| EP-3914592-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154431-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | LYNCH KEVIN R (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154431-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | LYNCH KEVIN R (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | FAAH 4190/4885MGLL 4803/4885HDAC4 2770/4885 |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | SPNS2, SLC20A2, S1PR2 | FAAH 3735/4885MGLL 1829/4885HDAC4 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.